Carla O’REilly

Carla O’REilly

Auto-generated profile, based on publicly available information

Carla O’REilly

St. Jude Children’s Research Hospital 1 Department of Bone Marrow Transplantation and Cellular Therapy Memphis, Tennessee

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
Purpose: Chimeric antigen receptor (CAR) T-cell therapy offers a promising approach to improve outcomes for patients with relapsed, refractory, or metastatic osteosarcoma. However, novel target antigens are needed to overcome obstacles limiting CAR T-cell efficacy against osteosarcoma and other solid tumors. Leucine-rich repeat-containing 15 (LRRC15) has been identified as a promising target in patients with osteosarcoma. Given these findings, we aimed to develop LRRC15-CAR T cells and evaluate their antitumor activity and safety in preclinical models. Experimental Design: We evaluated LRRC15 expression in normal tissues and pediatric solid tumors using gene expression and immunohistochemical (IHC) approaches. We generated LRRC15-CAR T cells using a binding domain that recognizes human and murine LRRC15 and evaluated their specificity, antitumor activity, and safety in preclinical studies. Results: Gene expression analysis demonstrated limited Lrrc15 expression in normal tissues and high expression in osteosarcoma, which was confirmed at the protein level by IHC staining of primary pediatric osteosarcoma tumors. In vitro, LRRC15-CAR T cells demonstrated specificity and cytotoxicity against LRRC15-positive targets. In vivo, LRRC15-CAR T cells exhibited antitumor activity in both human xenograft and immunocompetent murine osteosarcoma models, leading to significantly increased survival compared with controls. Finally, comprehensive toxicity analysis demonstrated a positive safety profile of intravenously administered LRRC15-CAR T cells. Conclusions: LRRC15-CAR T cells exert anti-osteosarcoma activity while maintaining a positive safety profile. These promising findings support the clinical translation of LRRC15-CAR T cells for patients with osteosarcoma and potentially other LRRC15-positive solid tumors.

17 June 2026
Verified
Other
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
LRRC15-CAR T cells exhibit transient antitumor activity and enhance survival in a bulky orthotopic limb osteosarcoma model

17 June 2026
Verified
Other
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
LRRC15-CAR T cell persistence in the OS152 orthotopic osteosarcoma model

17 June 2026
Verified
Other
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
Pre-infusion healthy donor T cell characteristics for in vivo studies

17 June 2026
Verified
Other
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
Extended LRRC15-CAR T Cell function in vitro

17 June 2026
Verified
Other
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
Purpose:Chimeric antigen receptor (CAR) T-cell therapy offers a promising approach to improve outcomes for patients with relapsed, refractory, or metastatic osteosarcoma. However, novel target antigens are needed to overcome obstacles limiting CAR T-cell efficacy against osteosarcoma and other solid tumors. Leucine-rich repeat-containing 15 (LRRC15) has been identified as a promising target in patients with osteosarcoma. Given these findings, we aimed to develop LRRC15-CAR T cells and evaluate their antitumor activity and safety in preclinical models.Experimental Design:We evaluated LRRC15 expression in normal tissues and pediatric solid tumors using gene expression and immunohistochemical (IHC) approaches. We generated LRRC15-CAR T cells using a binding domain that recognizes human and murine LRRC15 and evaluated their specificity, antitumor activity, and safety in preclinical studies.Results:Gene expression analysis demonstrated limited Lrrc15 expression in normal tissues and high expression in osteosarcoma, which was confirmed at the protein level by IHC staining of primary pediatric osteosarcoma tumors. In vitro, LRRC15-CAR T cells demonstrated specificity and cytotoxicity against LRRC15-positive targets. In vivo, LRRC15-CAR T cells exhibited antitumor activity in both human xenograft and immunocompetent murine osteosarcoma models, leading to significantly increased survival compared with controls. Finally, comprehensive toxicity analysis demonstrated a positive safety profile of intravenously administered LRRC15-CAR T cells.Conclusions:LRRC15-CAR T cells exert anti-osteosarcoma activity while maintaining a positive safety profile. These promising findings support the clinical translation of LRRC15-CAR T cells for patients with osteosarcoma and potentially other LRRC15-positive solid tumors.